A deal to take Seattle biotech company Intrinsic Medicine public via a SPAC merger has fallen apart. The SPAC deal, announced in October, would have taken...
FOR RELEASE AT: Thursday, December 1, at 2 p.m. US ET Credit: UNC School of Medicine FOR RELEASE AT: Thursday, December 1, at 2 p.m. US...
In its third quarter report, Oncorus highlighted that it would report updated Phase I data on its lead candidate, an oncolytic virus therapy for solid...
Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of The post mRNA can deliver universal flu vaccine,...
Daiichi Sankyo shut down its South San Francisco subsidiary Plexxikon earlier this year. Now a new startup is looking to forge its own path — with...
The COVID-19 pandemic stopped the world in its tracks. It provided a range of new challenges for industry The post Overcoming the challenges of developing...
CytoDyn Inc (OTCMKTS: CYDY) has formed a solid base over $0.30 and is beginning to move northbound again. The stock recently made a solid bounce from...
Researchers at the University of Texas at Arlington, in collaboration with Shani Biotechnologies, a local firm, have created a point-of-care device that...
A multidisciplinary team of Weill Cornell Medicine researchers have received a five-year $5.7 million grant from the National Cancer Institute at the...
This year, with Nasdaq iced over, everything is falling behind. A quick turn to CDER’s approvals for the year reveals that the group has stamped an...
During Chardan's recent 6th Annual Genetic Medicines Conference in New York, held in-person for the first time since the COVID-19 pandemic, leaders from...
In the near future, painful jabs and muscle soreness that persists for days could be replaced by new immunization approaches including intradermal delivery,...
West London may not have been an obvious choice for a growing biotech company, but Avacta Therapeutics might be on to something by moving away from...
A new animal study from Katherine Lee, a researcher with the West Virginia University School of Medicine, investigates why individuals with obesity...
The US authorities have authorised use of two bivalent COVID-19 booster vaccines from Pfizer/BioNTech and Moderna – targeting The post US clears Omicron...
Amgen is equipped with a broad and diverse product portfolio, commercial capabilities, and levers for delivering mid-single digit revenue growth over this...
AbbVie may have doubled in size since the Allergan acquisition, but nearly half the company’s revenue, and a large chunk of its potential future growth,...
Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating...
It might seem like luck for a company to trip over a multi-billion dollar COVID treatment already lurking in its pipeline – but perhaps not so...
With Celgene and other acquisition costs in the rearview, Bristol Myers Squibb returned to profitability with a vengeance in 2021.
Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by...
Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of October 3. Aside from presenting a synopsis of events, we provide market...
In this GEN webinar, sponsored by Integral Molecular, panelists Dr. Sheila Keating and Dr. Natalie Anosova will describe how Integral Molecular’s extensive...
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable...
Nenad Grmusa Nenad Grmusa was “really happy” at Takeda, where he’d been for more than a decade in various R&D strategy and finance positions....
Moderna CEO Stéphane Bancel made clear on the last quarterly call that “now is not the time to slow down.” On Thursday, he made a bit...
UCLA scientists report positive preclinical results on the safety and efficacy of an RNA vaccine (ZVAX) against the mosquito borne Zika virus that severely...
In the Phase II VISIONARY-MS trial (NCT03536559), which evaluated CNM-Au8 in participants with stable relapsing remitting multiple sclerosis (RRMS), CNM-Au8...
A submission to the US Food and Drug Administration (FDA) requesting an Emergency Use Authorization (EUA) of a The post Pfizer/BioNTech ask FDA for EUA...
A Prime Medicine IPO is preparing to hit the market, and many investors will look to benefit from this biotech startup. The post Prime Medicine IPO:...